Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab + Durvalumab + FLOT in HER2-Positive Gastric or GEJ Cancer
NCT07911280Phase 2Recruiting
- Sponsor
- Samsung Medical Center
- Start
- Oct 2026
- Primary completion
- Jan 2030
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab and trastuzumab in gastric cancer (GC) and gastroesophageal junction cancer, sponsored by Samsung Medical Center. Primary endpoints: Pathologic Complete Response Rate and Number of Participants With Treatment-Related Adverse Events. Started Oct 2026; status: recruiting.
02
Drugs
durvalumabtrastuzumab
03
Conditions
gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT07911280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07911280.